| Title |
|
Immuno-oncology therapy associated thromboembolic events in metastatic renal cell carcinoma. |
|
|
| Publication Date |
|
| Author(s) |
|
| Subject |
|
Metastatic renal cell carcinoma |
|
|
| Type of document |
|
| OrcId |
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
| DOI |
|
10.1016/j.eucr.2023.102420 |
|
|
| Abstract |
|
The relationship between thromboembolic events (TEs) and immune-oncology (IO) agents in patients with metastatic renal cell carcinoma (mRCC) with inferior-vena-cava (IVC) thrombus has not been explored despite conferring significant morbidity. A late 30s female is diagnosed with mRCC with a level-II IVC thrombus after presenting with back pain. Two weeks post initiation of immunotherapy, she re-presented with bilateral sub-massive pulmonary emboli requiring IVC and pulmonary thrombectomy. This case exposes a potential relationship between mRCC and IVC thrombus with IO agents that creates a critically hypercoagulable state. This issue requires further investigation given the apparent under-reporting of TEs in these patients. |
|
|
| Link |
|
| Citation |
|
Urology Case Reports 2023-07; 49 |
|
|
| Jornal Title |
|
